Titan Pharmaceuticals Inc (TTNP)

5.76
0.11 1.90
NASDAQ : Health Care
Prev Close 5.87
Open 5.83
Day Low/High 5.71 / 5.88
52 Wk Low/High 2.57 / 10.00
Volume 92.67K
Avg Volume 162.90K
Exchange NASDAQ
Shares Outstanding 21.20M
Market Cap 123.80M
EPS 0.70
P/E Ratio 8.23
Div & Yield N.A. (N.A)

Latest News

Probuphine® (buprenorphine) Implant Phase 3 Data Presented At CPDD Annual Scientific Meeting

Probuphine® (buprenorphine) Implant Phase 3 Data Presented At CPDD Annual Scientific Meeting

Results Demonstrate the Superiority of Probuphine for Abstinence from Opioids for Patients over Six Months

Braeburn Pharmaceuticals Announces FDA Approves Probuphine® (buprenorphine) Implant: The First Implant For Treatment Of Opioid Dependence

Braeburn Pharmaceuticals Announces FDA Approves Probuphine® (buprenorphine) Implant: The First Implant For Treatment Of Opioid Dependence

Patients and Providers Have a New Option to Combat Opioid Dependence

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share look ready to break out and trade higher from current levels.

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

Titan Pharmaceuticals (TTNP) stock is climbing after the FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of approving the company's treatment for opioid addiction.

4 Biotech Stocks Under $10 to Trade for Big Breakouts

4 Biotech Stocks Under $10 to Trade for Big Breakouts

These under-$10 biotech stocks are within range of triggering major breakout trades.

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

Titan and its partner will resubmit Probuphine for FDA approval later this year.

TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach Of Fiduciary Duty

TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals,...

FDA Rejection of Titan's Probuphine Looks Like a Mugging

FDA Rejection of Titan's Probuphine Looks Like a Mugging

FDA find much at fault with Titan's implantable therapy for opioid dependence.

Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy

Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Titan Pharma: FDA Panel Live Blog

Titan Pharma: FDA Panel Live Blog

Join TheStreet's Adam Feuerstein for his live blog covering the FDA panel reviewing Titan's treatment for opioid addiction.

The Next Big Thing In Biotech: Titan

The Next Big Thing In Biotech: Titan

Titan Pharmaceuticals is the next big thing in biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma

Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Titan Pharma: Run-Up Trade Into March FDA Panel

Titan Pharma: Run-Up Trade Into March FDA Panel

I expect traders will get an opportunity to profit from increased focus on Titan through March.